Repositioning Candidate Details
| Candidate ID: | R1369 |
| Source ID: | DB11358 |
| Source Type: | investigational; nutraceutical |
| Compound Type: | biotech |
| Compound Name: | Evening primrose oil |
| Synonyms: | Oenothera biennis (evening primrose) oil; Oenothera biennis (evening primrose) seed extract; Oenothera biennis l. oil; Oenothera biennis seed extract; Oenothera biennis seed oil; Oenothera lamarckiana l. oil; Oenothera muricata seed oil; Oenothera oil; Oenothera pycnocarpa seed oil; Oenotherae biennis oleum; Oils, glyceridic, evening primrose; Oleum oenotherae erythrospinae; Primrose oil |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Evening primrose oil comes from the extraction from _Oenothera biennis_ seeds and it is commonly used as an alternative source for omega-6 essential fatty acids. In its composition it presents some fatty acids such as and . Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety". By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements. By the EMA, evening primrose oil is approved in herbal preparations. |
| CAS Number: | 308064-97-3 |
| Molecular Weight: | |
| DrugBank Indication: | Evening primrose oil is used as part of over-the-counter dietary supplements. It is also used for the treatment of systemic inflammatory diseases and for women's health conditions such as cyclical mastalgia. These indications do not have sufficient evidence of their effectiveness. It was used for the treatment of atopic dermatitis in the United Kingdom but it is currently withdrawn due to lack of evidence of effectiveness. |
| DrugBank Pharmacology: | The effectivity of evening primrose oil is debatable as the evidence is very limited. Evening primrose oil improves the essential fatty acid content in plasma, erythrocyte, and platelet lipids. It has also been registered to increase alpha-tocopherol levels in non-diabetic and type I diabetic patients. Evening primrose oil affects the fatty acid composition of serum lipids and adipose tissue as well as it helps maintain normal cellular structures and it serves as a prostaglandin precursor. Administration of evening primrose oil is part of long-term therapy and thus, immediate results are never expected. |
| DrugBank MoA: | Evening primrose oil presents a content of 74% and 9% from which the later seems to be the key active ingredient of this oil. These major essential fatty acids are required for the normal structure of cell membranes and they are not synthesized endogenously. The therapeutic activity of evening primrose oil is attributed to the direct action of its essential fatty acids on immune cells as well as to an indirect effect on the synthesis of eicosanoids. The actions of highly unsaturated fatty acids in tissues and eicosanoids are thought to be implicated in inflammatory and immunologic pathogeneses. The essential fatty acids found in evening primrose oil are involved in the biosynthesis of prostaglandin. For this activity, the main involved component is the . The presence of this essential fatty acid allows the synthesis of anti-inflammatory substances such as 15-hydroxy-eicosatrienoic acid and prostaglandin E1. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|